| Schedule of Financial Statement Information |
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
|
December 31, |
|
(In thousands) |
|
2025 |
|
|
2024 |
|
Accounts receivable, net: |
|
|
|
|
|
|
Accounts receivable |
|
$ |
101,043 |
|
|
$ |
119,284 |
|
Less: allowance for credit losses |
|
|
(1,667 |
) |
|
|
(1,267 |
) |
|
|
$ |
99,376 |
|
|
$ |
118,017 |
|
Inventories, net: |
|
|
|
|
|
|
Consumable supplies |
|
$ |
14,284 |
|
|
$ |
15,488 |
|
Finished products |
|
|
42,201 |
|
|
|
32,310 |
|
Work in-process |
|
|
2,545 |
|
|
|
2,355 |
|
Raw materials |
|
|
11,512 |
|
|
|
9,418 |
|
Less: inventory reserve |
|
|
(4,197 |
) |
|
|
(2,774 |
) |
|
|
$ |
66,345 |
|
|
$ |
56,797 |
|
Other current assets and prepaid expenses: |
|
|
|
|
|
|
Escrow receivable |
|
$ |
24,390 |
|
|
$ |
23,750 |
|
Taxes recoverable |
|
|
8,337 |
|
|
|
8,266 |
|
Prepaid expenses |
|
|
11,026 |
|
|
|
6,785 |
|
Prepaid insurance |
|
|
4,178 |
|
|
|
3,818 |
|
Other receivables |
|
|
2,474 |
|
|
|
2,015 |
|
Other |
|
|
8,478 |
|
|
|
10,705 |
|
|
|
$ |
58,883 |
|
|
$ |
55,339 |
|
Intangible assets, net: |
|
|
|
|
|
|
Customer relationships |
|
$ |
206,480 |
|
|
$ |
255,430 |
|
Technologies |
|
|
814,733 |
|
|
|
806,858 |
|
Trade names |
|
|
49,770 |
|
|
|
49,726 |
|
Covenants not to compete |
|
|
12,926 |
|
|
|
12,906 |
|
Licenses |
|
|
6,423 |
|
|
|
6,316 |
|
Product registrations |
|
|
6,751 |
|
|
|
6,172 |
|
Other |
|
|
8,614 |
|
|
|
5,729 |
|
Less: accumulated amortization |
|
|
(549,709 |
) |
|
|
(526,524 |
) |
|
|
$ |
555,988 |
|
|
$ |
616,613 |
|
Accrued expenses: |
|
|
|
|
|
|
Employee benefits and severance |
|
$ |
32,563 |
|
|
$ |
34,167 |
|
Clinical trials |
|
|
6,956 |
|
|
|
6,104 |
|
Commitments and contingencies |
|
|
5,436 |
|
|
|
9,850 |
|
Accrued interest |
|
|
5,512 |
|
|
|
8,313 |
|
Gross to net provision |
|
|
5,347 |
|
|
|
6,920 |
|
Inventory received but not invoiced |
|
|
1,962 |
|
|
|
2,146 |
|
Finance leases short-term |
|
|
1,566 |
|
|
|
1,679 |
|
Professional fees |
|
|
1,587 |
|
|
|
2,521 |
|
Taxes payable |
|
|
9,605 |
|
|
|
22,275 |
|
Royalties |
|
|
762 |
|
|
|
563 |
|
Commissions |
|
|
1,577 |
|
|
|
1,434 |
|
Other |
|
|
17,682 |
|
|
|
22,385 |
|
|
|
$ |
90,555 |
|
|
$ |
118,357 |
|
Other long-term liabilities: |
|
|
|
|
|
|
Employee severance |
|
$ |
9,904 |
|
|
$ |
14,269 |
|
Mortgages and other debts payable |
|
|
2,773 |
|
|
|
3,002 |
|
Finance leases long-term |
|
|
3,689 |
|
|
|
4,064 |
|
Other |
|
|
11,441 |
|
|
|
11,503 |
|
|
|
$ |
27,807 |
|
|
$ |
32,838 |
|
|
| Schedule of Goodwill |
The following table summarizes the changes in Goodwill by reporting unit during the six months ended June 30, 2025.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2025 |
|
(In thousands) |
|
Gross
goodwill at
January 1,
2025 |
|
|
Cumulative
impairment
at
January 1 |
|
|
Acquisitions,
dispositions
and other |
|
|
Foreign
exchange
and other |
|
|
Balance at June 30, 2025 |
|
Pharmaceuticals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURNA |
|
$ |
4,827 |
|
|
$ |
(4,827 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Rayaldee |
|
|
79,433 |
|
|
|
— |
|
|
|
— |
|
|
|
10,099 |
|
|
|
89,532 |
|
FineTech |
|
|
11,698 |
|
|
|
(11,698 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
ModeX |
|
|
80,260 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
80,260 |
|
OPKO Biologics |
|
|
139,784 |
|
|
|
— |
|
|
|
— |
|
|
|
(0 |
) |
|
|
139,784 |
|
OPKO Chile |
|
|
3,220 |
|
|
|
— |
|
|
|
— |
|
|
|
205 |
|
|
|
3,425 |
|
OPKO Health Europe |
|
|
6,848 |
|
|
|
— |
|
|
|
— |
|
|
|
894 |
|
|
|
7,742 |
|
OPKO Mexico |
|
|
100 |
|
|
|
(100 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Transition Therapeutics |
|
|
3,421 |
|
|
|
(3,421 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BioReference |
|
|
219,707 |
|
|
|
— |
|
|
|
(56,265 |
) |
|
|
— |
|
|
|
163,442 |
|
OPKO Diagnostics |
|
|
17,977 |
|
|
|
(17,977 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
567,275 |
|
|
$ |
(38,023 |
) |
|
$ |
(56,265 |
) |
|
$ |
11,198 |
|
|
$ |
484,185 |
|
|